NeuroMetrix to Exhibit at American Diabetes Association’s 73rd Scientific SessionsWALTHAM, Mass.--(BUSINESS WIRE)--Jun. 10, 2013--
NeuroMetrix,
Inc. (Nasdaq: NURO), a medical device company focused on the
diagnosis and treatment of the neurological complications of diabetes,
reported today that it will exhibit and participate in the American
Diabetes Association’s (ADA) 73
rd Scientific Sessions. The
ADA Scientific Sessions will be held on
June 22-24 in
Chicago at the
McCormick Place Convention Center.
NeuroMetrix will feature its first therapeutic product, the SENSUS™
Pain Management System, which was launched during the first quarter of
2013. SENSUS is a transcutaneous electrical nerve stimulator intended
for the symptomatic relief and management of chronic intractable pain.
It is the only device designed specifically for people with diabetes and
chronic pain. The most common cause of such pain in people with diabetes
is painful diabetic neuropathy (PDN), which affects up to 5 million
people in the US alone. Most patients with PDN have moderate to severe
pain and half have sleep disturbances due to their pain. SENSUS offers
physicians and their patients a non-narcotic pain relief option as a
complement to medications. The device is lightweight, can be worn during
the day, and may be used at bedtime before going to sleep. It is
activated by the press of a single button.
The Company will also conduct a meeting of its scientific advisory board
consisting of international leaders in the detection, management, and
treatment of the neurological complications of diabetes. Attendees are
encouraged to visit NeuroMetrix at booth #947.
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment of diabetic
neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for
treating chronic pain, focusing on physicians managing patients with
painful diabetic neuropathy and similar peripheral neuropathies. The
company also markets the NC-stat® DPNCheck®
device, which is a rapid, accurate, and quantitative point-of-care test
for diabetic neuropathy. This product is used to detect diabetic
neuropathy at an early stage and to guide treatment. For more
information, please visit http://www.neurometrix.com.
Source: NeuroMetrix
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
